Geneva and Basel, Switzerland, 2005/10/26
Geneva Bioinformatics (GeneBio) SA, producer of world-class proteomics software, and Genedata AG, global provider of computational solutions for drug discovery and development, today announced a collaboration that will offer life science researchers a precise, high-throughput solution for analyzing proteomics data. The two companies will integrate the Genedata Expressionist® solution with the Melanie/ImageMaster™ 2D Platinum solution, forming a seamless analysis workflow.
“There is a growing need for integrated, reproducible and scalable methods to exploit proteomics data”, explained Nasri Nahas, CEO of GeneBio. “The next phase in the collaboration involves incorporating Expressionist with GeneBio’s Phenyx mass spectrometry (MS) data analysis platform, specifically designed to meet the concurrent demands of high-throughput MS data analysis and dynamic results assessment. This collaboration builds on synergies between our systems and delivers robust automation of proteomics analysis."
“We are pleased to have the opportunity to combine our high-throughput systems with GeneBio’s renowned proteomics software”, said Dr Daniel Keesman, CEO of Genedata AG. Combined with the Melanie platform, the complete solution is suited to high-throughput proteomics applications including biomarker-based preclinical research. “Automating the validation and analysis of 2D gel data is just one example of how the collaboration will save time and expensive laboratory consumables in high-throughput proteomics.”
Genedata Expressionist® automates analysis workflows from sample validation through to biological interpretation and result management. The Melanie two-dimensional gel electrophoresis (2-DE) analysis solution was developed by the Swiss Institute of Bioinformatics (SIB) and GeneBio; it now powers GE Healthcare’s ImageMaster™ 2D Platinum platform.
Contact
Genedata AG
Tobe Freeman
Marketing Communications
Phone +41 61 697 8510
Fax +41 61 697 7244
Tobe.Freeman@genedata.com
www.genedata.com
Geneva Bioinformatics (GeneBio) SA
Andrew Smith
Marketing Manager
Phone +41 22 702 99 00
Fax +41 22 702 99 99
andrew.smith@genebio.com
www.genebio.com
About Genedata
Genedata specializes in computational solutions for life science research, drug discovery, and drug development. The Company combines a comprehensive, scientifically validated computational platform with expert scientific consulting services to provide tailor-made solutions for specific applications and multiple therapeutic areas. Founded in 1997 as a spin-off from Novartis, the Company is privately held and has grown to an interdisciplinary, international team of dedicated experts. Genedata is headquartered in Basel (Switzerland) with subsidiaries and branch offices in Munich (Germany), San Francisco (USA), and Boston (USA). The Company is also represented by Infocom Corporation (Japan), DigiGenomics (Taiwan), and Research Instruments (Singapore, Malaysia). For more information about Genedata, please visit: www.genedata.com.
About GeneBio
Founded in 1997, GeneBio is a multifaceted bioinformatics company situated at the heart of the Lake Geneva Region, one of the world’s major proteomics centres of excellence. Based on expertise in the proteomics and bioinformatics fields, GeneBio offers original educational and knowledge-discovery solutions that help clients shape heterogeneous information into relevant biological knowledge. For more information about GeneBio, please visit: www.genebio.com.
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Related Files:
Dowload in PDF format